Interferon-mediated repression of miR-324-5p potentiates necroptosis to facilitate antiviral defense

EMBO Rep. 2022 Aug 3;23(8):e54438. doi: 10.15252/embr.202154438. Epub 2022 Jun 23.

Abstract

Mixed lineage kinase domain-like protein (MLKL) is the terminal effector of necroptosis, a form of regulated necrosis. Optimal activation of necroptosis, which eliminates infected cells, is critical for antiviral host defense. MicroRNAs (miRNAs) regulate the expression of genes involved in various biological and pathological processes. However, the roles of miRNAs in necroptosis-associated host defense remain largely unknown. We screened a library of miRNAs and identified miR-324-5p as the most effective suppressor of necroptosis. MiR-324-5p downregulates human MLKL expression by specifically targeting the 3'UTR in a seed region-independent manner. In response to interferons (IFNs), miR-324-5p is downregulated via the JAK/STAT signaling pathway, which removes the posttranscriptional suppression of MLKL mRNA and facilitates the activation of necroptosis. In influenza A virus (IAV)-infected human primary macrophages, IFNs are induced, leading to the downregulation of miR-324-5p. MiR-324-5p overexpression attenuates IAV-associated necroptosis and enhances viral replication, whereas deletion of miR-324-5p potentiates necroptosis and suppresses viral replication. Hence, miR-324-5p negatively regulates necroptosis by manipulating MLKL expression, and its downregulation by IFNs orchestrates optimal activation of necroptosis in host antiviral defense.

Keywords: MLKL; antiviral defense; interferon; miR-324-5p; necroptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents
  • Humans
  • Influenza A virus*
  • Interferons
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Necroptosis
  • Virus Replication / physiology

Substances

  • Antiviral Agents
  • MIRN324 microRNA, human
  • MicroRNAs
  • Interferons